PERSPECTA

News from every angle

← Back to headlines

Teva and Sanofi Report Positive Phase 2b Results for Ulcerative Colitis and Crohn's Disease Drug

Teva and Sanofi announced durable phase 2b efficacy results for their drug duvakitug, intended for the treatment of ulcerative colitis and Crohn's disease.

17 Feb, 11:15 — 17 Feb, 11:15
PostShare
ℹOnly 1 source covers this story

Read at source (1 outlet)

seeking-alpha15d ago

Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease

Read full article →

Related Stories

Obesity as a silent epidemic, with children increasingly affected

10m ago

Vi lever længere - men flere lever med langvarig sygdom

19m ago

This Diet Reduces Dementia Risk by 41% – Research

19m ago

Our 11-year-old has ADHD and gets overwhelmed and aggressive at times – what can we do to help him?

20m ago